Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read more at globenewswire.com